Effect of Thiazolidinediones on the erythropoeitic and germinal cells in the male Wistar rats

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 423-429

  Rabbani, Syed Imam ^a   Devi, Kshama ^a   Khanam, Salma ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Micronucleus test; Pioglitazone; Rosiglitazone; Sperm shape morphology

Indexed keywords

EID: 58049090115     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s678     Document Type: Article

References (28)

1. Accessed 10 February. URL: http://www.gsk/avandamet/monograph/pdf
2. Accessed 27 January 2006. URL: http://www.oecd.org/dataoecd/18/34/1948442.pdf
3. Balfour, J.A., Plosker, G.J. 1999. Rosiglitazone. Drugs, 57: 921-30.
4. Bao, Y., Jia, R.H., Yuan, J. et al. 2007. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its down stream signaling pathways. Pharmacol., 80(1):57-64.
5. Baynes, J.W. 1991. Role of oxidative stress in development of complications of diabetes. Diabetes, 40:405-12.
6. Bedir, A., Aliyazicioglu, Y., Bilgiri, B. et al. 2008. Assessment of genotoxicity in rats treated with the antidiabetic agent. Pioglitazone. Environ. Mol. Mutagen., 49:185-91.
7. Bedir, A., Aliyazicioglu, Y., Kahraman, H. et al. 2006. Genotoxicity in rats treated with the antidiabetic agent, Rosiglitazone. Environ. Mol. Mutagen., 47:718-24.
8. Berger, J. and Moller, D.E. 2002. The mechanisms of action of PPARs. Annu. Rev. Med., 53:409-35.
9. Chinetti, G., Fruchart, J.C. and Steals, B. 2000. Peroxisome proliferators-activator receptors (PPARs): nuclear receptors at the cross roads between lipid metabolism and inflammation. Inflamm. Res., 49:497-505.
10. Gaikwad, A.B., Viswanad, B. and Ramarao, P. 2007. PPAR. gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacol. Res., 55(5):400-7.
11. Galli, A., Mello, T., Ceni, E. et al. 2006. The potential of antidiabetic Thiazolidinediones for anticancer therapy. Expert Opin. Investig. Drugs, 15(9):1039-49.
12. Gillies, P.S. and Dunn, C.J. 2000. Pioglitazone. Drugs, 60:333-43.
13. Gumieniczek, A. 2005. Effects of Pioglitazone on hyperglycemia induced alterations in antioxidative system in tissues of alloxan treated diabetic animals. Exp. Toxicol. Pathol., 56:321-6.
14. Hans, S., Zheug, Y. and Roman, J. 2007. Rosiglitazone, an agonist of PPAR. gamma, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR. Res., 29632.
15. Haskins, J.R., Rowse, P. and Rahbari, R. 2001. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent mutiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leucocytes. Arch. Toxicol., 75:425-38.
16. Kohlroser, J., Mathai, J., Reichheld, J. et al. 2000. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to United States Food and Drug Administration. Am. J. Gastroenterol., 95:272-6.
17. Krishna, G. and Hayashi, M. 2000. In vivo rodent micronucleus assay: protocol, conduct and data interpretation. Mutat. Res., 455:155-66.
18. Kumar, R.T., Doreswamy, K., Shrilatha, B. et al. 2002. Oxidative stress associated DNA damage in testis of mice: induction of abnormal sperms and effects on fertility. Mutat. Res., 513:103-11.
19. MacGregor, J.T., Heddle, J.A., Hite, M. et al. 1987. Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes. Mutat. Res., 189:103-12.
20. Ramachandran, A., Snehalatha, C. and Viswanathan, V. 2002. Burden of type 2 diabetes and its complications-The Indian scenario. Current Sci., 83(12):1471-76.
21. Renner, H.W. and Munzner, H. 1980. Mutagenicity of sulphonylureas. Mutat. Res., 77:347-55.
22. Saiki, R., Okazaki, M., Iwai, S. et al. 2007. Effect of Pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high fat diet and sucrose solution. J. Pharmacol. Sci., 105(2):156-67.
23. Sharabi, Y., Oron-Herman, M., Kamari, Y. et al. 2007. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed model. Am. J. Hypertens, 20(2):206-10.
24. Singh, P., Jain, A. and Kaur, G. 2004. Impact of hypoglycemia and diabetes on CNS: Correlation of mitochondrial oxidative stress with DNA damage. Mol. Cell. Biochem., 260:153-9.
25. Sugimura, A., Kiriyama, Y., Nochi, H. et al. 1999. Troglitazone suppress cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem. Biophys. Res. Commun., 261(3):833-7.
26. Takizawa, S. and Horii, I. 2002. Endocrinological assessment of toxic effects on the male reproductive system in rats treated with 5-flourouracil for 2 or 4 weeks. J. Toxicol. Sci., 27:49-56.
27. Vijaylaxmi, K.K. and Venu, R. 1999. In vivo anti clastogenic effects of L-Ascorbin acid in mice. Mutat. Res., 438:47-51.
28. Wyrobek, A.J. and Bruce, W.R. 1975. Chemical induction of sperm abnormalities in mice. Proc. Natl. Acad. Sci., U.S.A. 72(11):4425-29.